AR and neoplasm: In that regard, increased tumour glycolysis is associated with castration-resistant metastatic PCa (mCRPC) and poor prognosis [26, 56], and a rise in glucose consumption marks out neuroendocrine differentiation and metastasis, a known molecular adaptation to androgen-deprivation and AR-targeting therapies [57, 58].